Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association
Authors:
- Rakesh GopinathannairRGRakesh Gopinathannair
- Brian OlshanskyBOBrian Olshansky
- Mina K. ChungMCMina K. Chung
- Steve GordonSGSteve Gordon
- Jose A. JoglarJJJose A. Joglar
- Gregory M. MarcusGMGregory M. Marcus
- Philip L. MarPMPhilip L. Mar
- Andrea M. RussoARAndrea M. Russo
- Uma N. SrivatsaUSUma N. Srivatsa
- Elaine Y. WanEWElaine Y. Wan
- on behalf of the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Genomic and Precision MedicOMon behalf of the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Genomic and Precision Medic
- 19 November 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (21) , e449-e465
Abstract
Cardiac arrhythmias are commonly noted in patients during infections with and recovery from COVID-19. Arrhythmic manifestations span the spectrum of innocuous and benign to life-threatening and deadly. Various pathophysiological mechanisms have been proposed. Debate continues on the impact of incident and exacerbated arrhythmias on the acute and chronic (recovery) phase of the illness. COVID-19 and COVID-19 vaccine–associated myocardial inflammation and autonomic disruption remain concerns. As the pandemic has transformed to an endemic, with discovery of new SARS-CoV-2 variants, updated vaccines, and potent antiviral drugs, vigilance for COVID-19–associated arrhythmic and dysautonomic manifestations remains. The objective of this American Heart Association scientific statement is to review the available evidence on the epidemiology, pathophysiology, clinical presentation, and management of cardiac arrhythmias and autonomic dysfunction in patients infected with and recovering from COVID-19 and to provide evidence-based guidance. The writing committee’s consensus on implications for clinical practice, gaps in knowledge, and directions for future research are highlighted.Keywords
This publication has 147 references indexed in Scilit:
- Association of Remdesivir use with bradycardia: A systematic review and meta‐analysisJournal of Medical Virology, 2023
- Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and MolnupiravirJAMA Network Open, 2022
- Prevalence of Select New Symptoms and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31 to 150 Days After Testing Positive or Negative for SARS-CoV-2JAMA Network Open, 2022
- Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the PandemicJAMA Network Open, 2021
- Investigational Treatments for COVID‐19 may Increase Ventricular Arrhythmia Risk Through Drug InteractionsCPT: Pharmacometrics & Systems Pharmacology, 2020
- Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy CasesJAMA Cardiology, 2020
- Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)JAMA Cardiology, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, ChinaIntensive Care Medicine, 2020
- Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndromeClinical Autonomic Research, 2011